Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for Bradmer Pharmaceuticals in a research note issued on Friday, November 8th. HC Wainwright analyst M. Colonnese now expects that the company will earn $0.47 per share for the quarter, down from their prior forecast of $0.52. HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.65 EPS, Q4 2025 earnings at $0.77 EPS and FY2025 earnings at $2.44 EPS.
Bradmer Pharmaceuticals Stock Performance
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported C($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of C($0.52) by C$0.34.
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Canadian Penny Stocks: Can They Make You Rich?
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
